Cytokine/Chemokine responses in activated CD4+ and CD8+ T cells isolated from peripheral blood, bone marrow, and axillary lymph nodes during acute simian immunodeficiency virus infection

Journal of Virology

Volumn 88, Issue 16, 2014, Pages 9442-9457

  Kenway Lynch, Carys S ^a   Das, Arpita ^a   Lackner, Andrew A ^a,b   Pahar, Bapi ^a,b  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CD23 ANTIGEN; CD28 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 17; INTERLEUKIN 2; MACROPHAGE DERIVED CHEMOKINE; MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; SCATTER FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AXILLARY LYMPH NODE; BLOOD; BONE; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL LOSS; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FEMALE; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIMIAN IMMUNODEFICIENCY VIRUS; UPREGULATION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; BONE MARROW; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; LYMPH NODES; LYMPHOCYTE ACTIVATION; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 84904916851     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00774-14     Document Type: Article

References (76)

1. Doherty M, Ford N, Vitoria M, Weiler G, Hirnschall G. 2013. The 2013 WHOguidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities. Curr. Opin. HIV AIDS 8:528-534. http://dx.doi.org/10.1097/COH.0000000000000008.
2. Burdo TH, Lackner A, Williams KC. 2013. Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol. Rev. 254:102-113. http://dx.doi.org/10.1111/imr.12068.
3. Vinikoor MJ, Cope A, Gay CL, Ferrari G, McGee KS, Kuruc JD, Lennox JL, Margolis DM, Hicks CB, Eron JJ. 2013. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J. Acquir. Immune Defic. Syndr. 62:505-508. http://dx.doi.org/10.1097/QAI.0b013e318285cd33.
4. Xu H, Wang X, Morici LA, Pahar B, Veazey RS. 2011. Early divergent host responses in SHIVsf162P3 and SIVmac251 infected macaques correlate with control of viremia. PLoS One 6(3):e17965. http://dx.doi.org/10.1371/journal.pone.0017965.
5. Kenway-Lynch CS, Das A, Pan D, Lackner AA, Pahar B. 2013. Dynamics of cytokine/chemokine responses in intestinal CD4+ and CD8+ T cells during acute simian immunodeficiency virus infection. J. Virol. 87: 11916-11923. http://dx.doi.org/10.1128/JVI.01750-13.
6. Delaloye J, De Bruin IJ, Darling KE, Reymond MK, Sweep FC, Roger T, Calandra T, Cavassini M. 2012. Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection. Cytokine 60: 338-340. http://dx.doi.org/10.1016/j.cyto.2012.07.027.
7. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. 2005. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16:159-178. http://dx.doi.org/10.1016/j.cytogfr.2005.01.004.
8. Zanin V, Delbue S, Marcuzzi A, Tavazzi E, Del Savio R, Crovella S, Marchioni E, Ferrante P, Comar M. 2012. Specific protein profile in cerebrospinal fluid from HIV-1-positive cART-treated patients affected by neurological disorders. J. Neurovirol. 18:416-422. http://dx.doi.org/10.1007/s13365-012-0109-y.
9. Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, Shearer GM. 1993. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J. Clin. Invest. 91:759-765. http://dx.doi.org/10.1172/JCI116294.
10. Klein SA, Dobmeyer JM, Dobmeyer TS, Pape M, Ottmann OG, Helm EB, Hoelzer D, Rossol R. 1997. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 11:1111-1118. http://dx.doi.org/10.1097/00002030-199709000-00005.
11. Maggi E, Mazzetti M, Ravina A, Annunziato F, de Carli M, Piccinni MP, Manetti R, Carbonari M, Pesce AM, del Prete G, et al. 1994. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 265:244-248. http://dx.doi.org/10.1126/science.8023142.
12. Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, Sekaly RP, Fauci AS. 1994. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 265:248-252. http://dx.doi.org/10.1126/science.8023143.
13. Gazzinelli RT, Makino M, Chattopadhyay SK, Snapper CM, Sher A, Hugin AW, Morse HC, III. 1992. CD4+ subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirusinduced immunodeficiency in mice. J. Immunol. 148:182-188.
14. Chakrabarti L, Isola P, Cumont MC, Claessens-Maire MA, Hurtrel M, Montagnier L, Hurtrel B. 1994. Early stages of simian immunodeficiency virus infection in lymph nodes. Evidence for high viral load and successive populations of target cells. Am. J. Pathol. 144:1226-1237.
15. Lackner AA, Vogel P, Ramos RA, Kluge JD, Marthas M. 1994. Early events in tissues during infection with pathogenic (SIVmac239) and nonpathogenic (SIVmac1A11) molecular clones of simian immunodeficiency virus. Am. J. Pathol. 145:428-439.
16. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358. http://dx.doi.org/10.1038/362355a0.
17. Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell Jt, Bixby D, Savona MR, Collins KL. 2010. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat. Med. 16:446-451. http://dx.doi.org/10.1038/nm.2109.
18. Lackner AA, Veazey RS. 2007. Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu. Rev. Med. 58:461-476. http://dx.doi.org/10.1146/annurev.med.58.082405.094316.
19. Burdo TH, Soulas C, Orzechowski K, Button J, Krishnan A, Sugimoto C, Alvarez X, Kuroda MJ, Williams KC. 2010. Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog. 6(4):e1000842. http://dx.doi.org/10.1371/journal.ppat.1000842.
20. Council NR. 2001. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
21. Valentine LE, Loffredo JT, Bean AT, Leon EJ, MacNair CE, Beal DR, Piaskowski SM, Klimentidis YC, Lank SM, Wiseman RW, Weinfurter JT, May GE, Rakasz EG, Wilson NA, Friedrich TC, O'Connor DH, Allison DB, Watkins DI. 2009. Infection with "escaped" virus variants impairs control of simian immunodeficiency virus SIVmac239 replication in Mamu-B*08-positive macaques. J. Virol. 83:11514-11527. http://dx.doi.org/10.1128/JVI.01298-09.
22. Cline AN, Bess JW, Piatak M, Jr, Lifson JD. 2005. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34:303-312. http://dx.doi.org/10.1111/j.1600-0684.2005.00128.x.
23. Pahar B, Li J, Rourke T, Miller CJ, McChesney MB. 2003. Detection of antigen-specific T cell interferon + expression by ELISPOT and cytokine flow cytometry assays in rhesus macaques. J. Immunol. Methods 282:103-115. http://dx.doi.org/10.1016/j.jim.2003.08.003.
24. Pahar B, Cantu MA, Zhao W, Kuroda MJ, Veazey RS, Montefiori DC, Clements JD, Aye PP, Lackner AA, Lovgren-Bengtsson K, Sestak K. 2006. Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV. Vaccine 24:6839-6849. http://dx.doi.org/10.1016/j.vaccine.2006.06.050.
25. Pahar B, Lackner AA, Veazey RS. 2006. Intestinal double-positive CD4+ CD8+ T cells are highly activated memory cells with an increased capacity to produce cytokines. Eur. J. Immunol. 36:583-592. http://dx.doi.org/10.1002/eji.200535520.
26. Das A, Xu H, Wang X, Yau CL, Veazey RS, Pahar B. 2011. Doublepositive CD21+ CD27+ B cells are highly proliferating memory cells and their distribution differs in mucosal and peripheral tissues. PLoS One 6(1):e16524. http://dx.doi.org/10.1371/journal.pone.0016524.
27. Pahar B, Lackner AA, Piatak M, Jr, Lifson JD, Wang X, Das A, Ling B, Montefiori DC, Veazey RS. 2009. Control of viremia and maintenance of intestinal CD4+ memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge. Virology 387:273-284. http://dx.doi.org/10.1016/j.virol.2009.02.014.
28. Wang X, Das A, Lackner AA, Veazey RS, Pahar B. 2008. Intestinal double-positive CD4+ CD8+ T cells of neonatal rhesus macaques are proliferating, activated memory cells and primary targets for SIVMAC251 infection. Blood 112:4981-4990. http://dx.doi.org/10.1182/blood-2008-05-160077.
29. Pahar B, Amedee AM, Thomas J, Dufour JP, Zhang P, Nelson S, Veazey RS, Bagby GJ. 2013. Effects of alcohol consumption on antigen-specific cellular and humoral immune responses to SIV in rhesus macaques. J. Acquir. Immune Defic. Syndr. 64:332-341. http://dx.doi.org/10.1097/QAI.0b013e31829f6dca.
30. Teigler JE, Iampietro MJ, Barouch DH. 2012. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J. Virol. 86:9590-9598. http://dx.doi.org/10.1128/JVI.00740-12.
31. Didier ES, Sugimoto C, Bowers LC, Khan IA, Kuroda MJ. 2012. Immune correlates of aging in outdoor-housed captive rhesus macaques (Macaca mulatta). Immun. Ageing 9:25. http://dx.doi.org/10.1186/1742-4933-9-25.
32. Asquith M, Pasala S, Engelmann F, Haberthur K, Meyer C, Park B, Grant KA, Messaoudi I. 2014. Chronic ethanol consumption modulates growth factor release, mucosal cytokine production, and microRNA expression in nonhuman primates. Alcohol. Clin. Exp. Res. 38:980-993. http://dx.doi.org/10.1111/acer.12325.
33. Yin J, Vahey MT, Dai A, Lewis MG, Arango T, Yalley-Ogunro J, Greenhouse J, Mendoza K, Khan A, Sardesai NY, Weiss W, Komisar J, Boyer JD. 2012. Plasmodium inui infection reduces the efficacy of a simian immunodeficiency virus DNA vaccine in a rhesus macaque model through alteration of the vaccine-induced immune response. J. Infect. Dis. 206:523-533. http://dx.doi.org/10.1093/infdis/jis404.
34. Goode D, Aravantinou M, Jarl S, Truong R, Derby N, Guerra-Perez N, Kenney J, Blanchard J, Gettie A, Robbiani M, Martinelli E. 2014. Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmission. PLoS One 9(5):e97767. http://dx.doi.org/10.1371/journal.pone.0097767.
35. Ramesh G, Benge S, Pahar B, Philipp MT. 2012. A possible role for inflammation in mediating apoptosis of oligodendrocytes as induced by the Lyme disease spirochete Borrelia burgdorferi. J. Neuroinflammation 9:72. http://dx.doi.org/10.1186/1742-2094-9-72.
36. Intlekofer AM, Thompson CB. 2013. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 94:25-39. http://dx.doi.org/10.1189/jlb.1212621.
37. Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. 2013. Reevaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. PLoS One 8(3):e60186. http://dx.doi.org/10.1371/journal.pone.0060186.
38. Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, Manabe YC, Nabatanzi R, Kamya MR, Cao H. 2011. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect. Dis. 11:43. http://dx.doi.org/10.1186/1471-2334-11-43.
39. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354. http://dx.doi.org/10.1038/nature05115.
40. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687. http://dx.doi.org/10.1038/nature04444.
41. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. 1993. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort study. J. Acquir. Immune Defic. Syndr. 6:904-912.
42. Schwartz RH. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349-1356. http://dx.doi.org/10.1126/science.2113314.
43. Yang LP, Byun DG, Demeure CE, Vezzio N, Delespesse G. 1995. Default development of cloned human naive CD4 T cells into interleukin-4-and interleukin-5-producing effector cells. Eur. J. Immunol. 25:3517-3520. http://dx.doi.org/10.1002/eji.1830251247.
44. Duffy D, Rouilly V, Libri V, Hasan M, Beitz B, David M, Urrutia A, Bisiaux A, Labrie ST, Dubois A, Boneca IG, Delval C, Thomas S, Rogge L, Schmolz M, Quintana-Murci L, Albert ML, Milieu Interieur C. 2014. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity 40:436-450. http://dx.doi.org/10.1016/j.immuni.2014.03.002.
45. Fleischer B, Schrezenmeier H. 1988. T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J. Exp. Med. 167:1697-1707.
46. Smith-Garvin JE, Koretzky GA, Jordan MS. 2009. T cell activation. Annu. Rev. Immunol. 27:591-619. http://dx.doi.org/10.1146/annurev.immunol.021908.132706.
47. McClary H, Koch R, Chisari FV, Guidotti LG. 2000. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J. Virol. 74:2255-2264. http://dx.doi.org/10.1128/JVI.74.5.2255-2264.2000.
48. Oldstone MB. 2013. Lessons learned and concepts formed from study of the pathogenesis of the two negative-strand viruses lymphocytic choriomeningitis and influenza. Proc. Natl. Acad. Sci. U. S. A. 110:4180-4183. http://dx.doi.org/10.1073/pnas.1222025110.
49. Mosmann TR, Sad S. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138-146. http://dx.doi.org/10.1016/0167-5699(96)80606-2.
50. Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, Overman RG, Ochsenbauer C, Edmonds TG, Kappes JC, Cunningham CK, Denny TN, Weinhold KJ, Ferrari G, Haynes BF, Koup RA, Graham BS, Roederer M, Tomaras GD. 2010. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 84:4998-5006. http://dx.doi.org/10.1128/JVI.00138-10.
51. Freel SA, Picking RA, Ferrari G, Ding H, Ochsenbauer C, Kappes JC, Kirchherr JL, Soderberg KA, Weinhold KJ, Cunningham CK, Denny TN, Crump JA, Cohen MS, McMichael AJ, Haynes BF, Tomaras GD. 2012. Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J. Virol. 86:6835-6846. http://dx.doi.org/10.1128/JVI.00437-12.
52. Regis EG, Barreto-de-Souza V, Morgado MG, Bozza MT, Leng L, Bucala R, Bou-Habib DC. 2010. Elevated levels of macrophage migration inhibitory factor (MIF) in the plasma of HIV-1-infected patients and in HIV-1-infected cell cultures: a relevant role on viral replication. Virology 399:31-38. http://dx.doi.org/10.1016/j.virol.2009.12.018.
53. Dinarello CA. 1991. Interleukin-1 and interleukin-1 antagonism. Blood 77:1627-1652.
54. Louie S, Cai J, Law R, Lin G, Lunardi-Iskandar Y, Jung B, Masood R, Gill P. 1995. Effects of interleukin-1 and interleukin-1 receptor antagonist in AIDS-Kaposi's sarcoma. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:455-460. http://dx.doi.org/10.1097/00042560-199504120-00004.
55. Poli G, Kinter AL, Fauci AS. 1994. Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc. Natl. Acad. Sci. U. S. A. 91:108-112. http://dx.doi.org/10.1073/pnas.91.1.108.
56. Zavala F, Rimaniol AC, Boussin F, Dormont D, Bach JF, Descamps-Latscha B. 1995. HIV predominantly induces IL-1 receptor antagonist over IL-1 synthesis in human primary monocytes. J. Immunol. 155:2784-2793.
57. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, Macdonald HR. 1987. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J. Immunol. 139:1546-1549.
58. Seckinger P, Williamson K, Balavoine JF, Mach B, Mazzei G, Shaw A, Dayer JM. 1987. A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J. Immunol. 139:1541-1545.
59. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. 1990. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 85:1694-1697. http://dx.doi.org/10.1172/JCI114622.
60. Arend WP. 2002. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 13:323-340. http://dx.doi.org/10.1016/S1359-6101(02)00020-5.
61. Cocchi F, Devico AL, Garzinodemo A, Arya SK, Gallo RC, Lusso P. 1995. Identification of RANTES, Mip-1-alpha, and Mip-1-beta as the major HIV-suppressive factors produced by Cd8+ T cells. Science 270:1811-1815. http://dx.doi.org/10.1126/science.270.5243.1811.
62. Ullum H, Lepri Alessandro C, Victor J, Aladdin H, Phillips Andrew N, Gerstoft J, Skinhoj P, Pedersen Bente K. 1998. Production of +-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1+ are associated with a decreased risk of HIV disease progression. J. Infect. Dis. 177:331-336. http://dx.doi.org/10.1086/514192.
63. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, Mackay CR, Koup RA. 1998. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology 244:66-73. http://dx.doi.org/10.1006/viro.1998.9082.
64. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringeri A, Santagostino E, Rappaport J, Feldman M, O'Brien SJ, Burny A, Gallo RC. 1998. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 95:3857-3861. http://dx.doi.org/10.1073/pnas.95.7.3857.
65. Lambert JS, Machado ES, Watson DC, Sill AM, Lim JK, Charurat M, Cunha SM, Afonso AO, Oliviera RH, Tanuri A, DeVico AL. 2007. Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children. Pediatr. Infect. Dis. J. 26:935-944. http://dx.doi.org/10.1097/INF.0b013e31812714db.
66. Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA. 1997. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology 234:340-348. http://dx.doi.org/10.1006/viro.1997.8673.
67. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, DeVico AL, Gallo RC. 1999. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc. Natl. Acad. Sci. U. S. A. 96:11986-11991. http://dx.doi.org/10.1073/pnas.96.21.11986.
68. Ansari AW, Bhatnagar N, Dittrich-Breiholz O, Kracht M, Schmidt RE, Heiken H. 2006. Host chemokine (C-C motif) ligand-2 (CCL2) is differentially regulated in HIV type 1 (HIV-1)-infected individuals. Int. Immunol. 18:1443-1451. http://dx.doi.org/10.1093/intimm/dxl078.
69. Sozzani S, Introna M, Bernasconi S, Polentarutti N, Cinque P, Poli G, Sica A, Mantovani A. 1997. MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. J. Leukoc. Biol. 62:30-33.
70. LaFranco-Scheuch L, Abel K, Makori N, Rothaeusler K, Miller CJ. 2004. High beta-chemokine expression levels in lymphoid tissues of simian/ human immunodeficiency virus 89.6-vaccinated rhesus macaques are associated with uncontrolled replication of simian immunodeficiency virus challenge inoculum. J. Virol. 78:6399-6408. http://dx.doi.org/10.1128/JVI.78.12.6399-6408.2004.
71. Lane BR, King SR, Bock PJ, Strieter RM, Coffey MJ, Markovitz DM. 2003. The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology 307:122-134. http://dx.doi.org/10.1016/S0042-6822(02)00045-4.
72. Reinhart TA, Fallert BA, Pfeifer ME, Sanghavi S, Capuano S, III, Rajakumar P, Murphey-Corb M, Day R, Fuller CL, Schaefer TM. 2002. Increased expression of the inflammatory chemokine CXC chemokine ligand 9/monokine induced by interferon-gamma in lymphoid tissues of rhesus macaques during simian immunodeficiency virus infection and acquired immunodeficiency syndrome. Blood 99:3119-3128. http://dx.doi.org/10.1182/blood.V99.9.3119.
73. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. 2009. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 361:1548-1559. http://dx.doi.org/10.1056/NEJMoa0903175.
74. Ascherl G, Sgadari C, Bugarini R, Bogner J, Schatz O, Ensoli B, Sturzl M. 2001. Serum concentrations of fibroblast growth factor 2 are increased in HIV type 1-infected patients and inversely related to survival probability. AIDS Res. Hum. Retroviruses 17:1035-1039. http://dx.doi.org/10.1089/088922201300343717.
75. Maier JA, Mariotti M, Albini A, Comi P, Prat M, Comogilio PM, Soria MR. 1996. Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. Int. J. Cancer 65:168-172. http://dx.doi.org/10.1002/(SICI)1097-0215(19960117)65:2168::AID-IJC73.0.CO;2-X.
76. Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar S, Hoffman SL, Weiss WR. 2000. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J. Immunol. 165: 3772-3781. http://dx.doi.org/10.4049/jimmunol.165.7.3772.